Name | Type | Description | Interventions |
---|
AL 10 mg QD 14-21 | Experimental | Participants received 10 mg birabresib/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle. | |
AL 20 mg QD 14-21 | Experimental | Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |
AL 40 mg QD 14-21 | Experimental | Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |
AL 20 mg BID 21-21 | Experimental | Participants received 20 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle. | |
AL 80 mg QD 14-21 | Experimental | Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |
AL 40 mg BID 14-21 | Experimental | Participants received 40 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle. | |
AL 120 mg QD 14-21 | Experimental | Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |
AL 120 mg QD 21-21 | Experimental | Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle. | |
AL 160 mg QD 14-21 | Experimental | Participants received 160 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |
AML de novo 80 mg QD 14-21 | Experimental | Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |
AML/MDS 80 mg QD 14-21 | Experimental | Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |
OHM 10 mg QD 21-21 | Experimental | Participants received 10 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle. | |
OHM 20 mg QD 21-21 | Experimental | Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle. | |
OHM 40 mg QD 21-21 | Experimental | Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle. | |
OHM 80 mg QD 21-21 | Experimental | Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle. | |
OHM 40 mg BID 21-21 | Experimental | Participants received 40 mg birabresib/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle. | |
OHM 120 mg QD 21-21 | Experimental | Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle. | |
OHM 120 mg QD 14-21 | Experimental | Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |
OHM 120 mg QD 5-7 | Experimental | Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle. | |
OHM 120 mg QD 7-21 | Experimental | Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle | |
OHM/DLBCL 80 mg QD 14-21 | Experimental | Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle. | |